Posted by Voriconazole/SBECD loaded ophthalmic hydrogel was prepared using Poloxamer 407, a thermosensitive polymer along with hydroxypropylmethylcellulose (HPMCE15) as gelling agents.
The molar ratio of the drug to SBECD (1:3), showing 42-fold increase in solubility, was chosen to prepare the inclusion complexes using the lyophilization method. The stability constant was found to be 721-m. ATIR peaks, DSC thermograms and NMR spectra indicate the inclusion behavior of Voriconazole and SBECD. In vitro and ex-vivo studies demonstrated that optimized formulation sustained the drug release for over 12 h. Cellular cytotoxicity on Human corneal epithelial cells showed that V-SBECD formulations do not cause corneal epithelial damage after 24 h. In-situ gel and marketed formulation have shown a markable reduction in the growth of the Aspergillus Niger. The optimized SBECD-loaded in-situ gel formulation (F10) did not vary significantly in pH, drug content, viscosity, and % cumulative drug release, signifying stable formulations when tested at 4, 25, and 40 °C.
SAMPATHI, S., MADDUKURI, S., RAMAVATH, R., DODOALA, S., & KUCHANA, V. (2024). MODIFIED CYCLODEXTRIN-BASED THERMOSENSITIVE IN SITU GEL FOR VORICONAZOLE OCULAR DELIVERY AGAINST FUNGAL KERATITIS. International Journal of Applied Pharmaceutics, 16(1), 150–160. https://doi.org/10.22159/ijap.2024v16i1.48817